Cargando…
The Second of Two One-Year, Multicenter, Open-Label, Repeat-Dose, Phase II Safety Studies of PrabotulinumtoxinA for the Treatment of Moderate to Severe Glabellar Lines in Adult Patients
BACKGROUND: PrabotulinumtoxinA is a 900-kDa botulinum toxin type A produced by Clostridium botulinum. OBJECTIVES: The authors sought to investigate the safety of prabotulinumtoxinA for treatment of glabellar lines. METHODS: This was a multicenter, open-label, repeat-dose, 1-year phase II safety stud...
Autores principales: | Lorenc, Z Paul, Adelglass, Jeffrey M, Avelar, Rui L, Baumann, Leslie, Beer, Kenneth R, Cohen, Joel L, Cox, Sue Ellen, Dayan, Steven H, Dover, Jeffrey S, Downie, Jeanine B, Draelos, Zoe Diana, Goldman, Mitchel P, Gross, John E, Joseph, John H, Kaufman-Janette, Joely, Moy, Ronald L, Nestor, Mark, Schlessinger, Joel, Smith, Stacy R, Weiss, Robert A |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8598184/ https://www.ncbi.nlm.nih.gov/pubmed/33944913 http://dx.doi.org/10.1093/asj/sjaa382 |
Ejemplares similares
-
Corrigendum to: The Second of Two One-Year, Multicenter, Open-Label, Repeat-Dose, Phase II Safety Studies of PrabotulinumtoxinA for the Treatment of Moderate to Severe Glabellar Lines in Adult Patients
por: Lorenc, Z Paul, et al.
Publicado: (2021) -
The First of Two One-Year, Multicenter, Open-Label, Repeat-Dose, Phase II
Safety Studies of PrabotulinumtoxinA for the Treatment of Moderate to Severe Glabellar
Lines in Adult Patients
por: Kaufman-Janette, Joely, et al.
Publicado: (2021) -
PrabotulinumtoxinA vs OnabotulinumtoxinA for the Treatment of Adult Males With Moderate to Severe Glabellar Lines: Post-hoc Analyses of the Phase III Clinical Study Data
por: Solish, Nowell, et al.
Publicado: (2022) -
Corrigendum to: The First of Two One-Year, Multicenter, Open-Label, Repeat-Dose, Phase II Safety Studies of PrabotulinumtoxinA for the Treatment of Moderate to Severe Glabellar Lines in Adult Patients
por: Kaufman-Janette, Joely, et al.
Publicado: (2021) -
Efficacy and Safety of PrabotulinumtoxinA for the Treatment of Glabellar Lines in Adult Subjects: Results From 2 Identical Phase III Studies
por: Beer, Kenneth R., et al.
Publicado: (2019)